301333 R&G PharmaStudies
- 48.38
- -0.43-0.88%
R&G PharmaStudies News
Norsk (301333): Stable revenue growth, profits are under short-term pressure due to equity incentives and amortization
Core view The company's revenue for 23 years was 720 million yuan, up 13% year on year, and net profit to mother increased 43% year on year. As the industry continues to be affected by investment and financing and continued intensification of competition, new contracts reached 976 million yuan, an increase of 976 million yuan over the previous year
Caixin Securities released a research report on April 25 stating that it gave Norsger (301333.SZ) an increase in holdings rating. The main reasons for the rating include: 1) incident: the company released the 2023 annual report and the first quarter repor
Caixin Securities released a research report on April 25 stating that it gave Norsger (301333.SZ) an increase in holdings rating. The main reasons for the rating include: 1) incident: the company released the 2023 annual report and the first quarter report of 2024; 2) clinical trial operation and on-site management services grew rapidly in 2023, and profit levels increased year-on-year; 3) domestic innovative drug policy support increased, and the company's business orders are expected to improve. (Mainichi Keizai Shimbun)
Norsk (301333): Increased profitability and continued order growth help long-term development
Incident: Norsk publishes its 2023 Annual Report and 2024 Quarterly Report. The company achieved revenue of 721 million yuan in 2023 (+13.15% YoY) and net profit of 163 million yuan (+43.27% YoY)
Express News | Northcog: Net profit increased 43.27% year-on-year in 2023, and plans to pay 10 to 2 yuan
Northgate (301333.SZ) announced first-quarter results, net profit of 23.489 million yuan, a decrease of 19.95%
Northgate (301333.SZ) released its report for the first quarter of 2024. The company's revenue was 177 million...
Norske (301333): Steady growth in clinical operations and SMO is optimistic about increasing market share of high-quality clinical CRO
The 2023 results are in line with our expectations, and the 2024Q1 results are lower than our expectations. The company announced its 2023 results: revenue of 720 million yuan, +13.15% year over year; net profit to mother of 160 million yuan, +43 year over year.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
CRO concept stocks surged higher in the afternoon. Zhaoyan Pharmaceutical rose more than 8%, Tiger Pharmaceuticals rose more than 7%, and Norske, Haoyuan Pharmaceuticals, and Pharmaceutical Stone Technology rose more than 4%.
Norske (301333.SZ): Harmonious Growth Phase II and Harmonious Health plan to reduce their total holdings by no more than 3%
Gelonghui (301333.SZ) announced that shareholders holding 4,800,000 shares of the company (accounting for 5.0000% of the company's total share capital) Harmonious Growth Phase II (Yiwu) Investment Center (“Harmonious Growth Phase II”) and shareholders holding 2,155,200 shares of the company (accounting for 2.2450% of the company's total share capital ratio), Zhuhai Harmonious Health Investment Fund (limited partnership) (“Harmonious Health”) plan to reduce their share holdings through bulk transactions and centralized bidding transactions. Proposed reduction of shareholding by 2,880,000, proposed reduction of holdings
Express News | Norsk: Shareholders plan to reduce their holdings by no more than 3%
Northcog (301333.SZ): As of February 20, 2024, the total number of shareholders of the company was 4,750
On February 22, GLONGHUI (301333.SZ) said on the interactive platform that as of February 20, 2024, the total number of shareholders of the company was 4,750.
Norske (301333.SZ): Plans to set up an industrial fund to invest in healthcare industries such as biomedical innovation and medical device companies in the early to medium term
Gelonghui, Feb. 19, 丨 Norske (301333.SZ) announced that the company held the 17th meeting of the fourth board of directors on February 19, 2024 to review and pass the “Proposal on Joint Investment with Professional Institutions to Establish Industrial Funds”. The board of directors agreed that the company and CICC Capital jointly invest in the establishment of an industrial fund Zhongjin Nuosghe (Beijing) partnership (limited partnership) (tentative name, final name is subject to registration by the market supervision and administration department, referred to as “this foreign investment”). The target amount of funds pledged for industrial funds is not less than RMB 500 million, and the initial pledge size is RMB 315 million. incorporation
Norsk (301333): Strong growth in performance, significant increase in profit margins
The company predicts a 36-53% year-on-year increase in net profit. The company's 2023 performance forecast: In 2023, net profit to mother was 15.4-1.74 billion yuan, up 36-53% year-on-year (median value of 44%), after deducting non-net profit1
Northcox (301333.SZ): 2023 net profit pre-increased 36% to 53%
Glonghui, January 29丨Norske (301333.SZ) announced the 2023 annual results forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 154 million yuan to 174 million yuan, an increase of 36% to 53% over the same period last year; net profit profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 123 million yuan to 138 million yuan, an increase of 21% to 36% over the same period last year. In 2023, the main reasons for the change in the company's expected performance compared to the same period last year are as follows: 1. Due to the company's management policy of reducing costs, increasing efficiency, and seeking steady progress, the company
Norsig (301333): Profit levels maintain steady growth, brand advantages help expand orders
Investment Highlights Recently, Norsig released its 2023 three-quarter report. In the first three quarters of 2023, the company achieved operating income of 525 million yuan (yoy +12.06%); net profit of 126 million yuan (yoy)
Norsig (301333): New orders continue to increase, profit growth exceeds expectations
Core Opinions The company released its 2023 three-quarter report, which continued to maintain high growth from the first half of the year. It achieved operating income of 525 million yuan in the first three quarters, an increase of 12.06% over the previous year. Achieved net profit of 126 million yuan, year-on-year
[BT Earnings Report Instantaneous Analysis] Northgate's 2023 Quarterly Report: Stable balance sheet, significant profit growth, and impressive cash flow performance
This financial report was announced on 2023-10-25 16:31:31. Norsiger (stock code: 301333) is a professional clinical trial outsourcing service provider, also known as a clinical CRO company. The company was founded in 2008 and is committed to providing comprehensive integrated services for the whole process of drug clinical research and development for global pharmaceutical companies and scientific research institutions. The company has a complete R&D service system, including quality management, expertise and regulatory knowledge, to help customers efficiently develop pharmaceuticals and medical devices in complex industry and regulatory environments. In recent years, the company's business scale has been growing steadily and profit
Norsig (301333): Steady revenue growth in the first three quarters and gradual release of profit elasticity
Revenue grew steadily in the first three quarters, and profit elasticity was gradually released. In the first three quarters of 2023, the company achieved revenue of 525 million yuan (+12.06%) and net profit of 126 million yuan (+50.11%), net profit of 126 million yuan (+50.11%), not net of net income
Norsig (301333) 2023 Q3 Report Commentary: Profit Side Achieves High Growth
Recently, the company released its 2023 three-quarter report. The first three quarters of 2023 achieved revenue of 525 million yuan, an increase of 12.06% over the previous year, net profit of 126 million yuan, a year-on-year increase of 50.11% over the previous year, net profit attributable to the mother, minus non-return net profit
Norsig (301333.SZ) released results for the first three quarters, with net profit of 126 million yuan, an increase of 50.11%
Northgate (301333.SZ) released its report for the third quarter of 2023, and achieved operating income of 5.25 in the first three quarters...
Northgate (301333.SZ): Grants 1,882.88 million restricted shares to 249 incentive recipients
GLONGHUI, Oct. 9 | Northgate (301333.SZ) announced that the company's board of directors determined that the grant date of the company's restricted shares was October 9, 2023, and awarded 19828.8 million restricted shares to 249 eligible incentive recipients at a grant price of 26.31 yuan/share.
Analysis
Price Target
No Data
